May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos

UCB drops $2B upfront for Candid Therapeutics' autoimmune T-cell engager cizutamig — their second billion-dollar deal in three weeks. FDA proposes withdrawing Amgen's Tavneos over data manipulation allegations. Pfizer/Arvinas' Veppanubecomes the first approved PROTAC degraderVisit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, UCB, Candid vTherapeutics, cizutamig, autoimmune, T-cell engager, BCMA, Amgen, Tavneos, avacopan, FDA withdrawal, Pfizer, Arvinas, Veppanu, vepdegestrant, PROTAC, Teva, Emalex, ecopipam, Tourette syndrome, Summit Therapeutics, ivonescimab, Harmoni-3, Axsome, Auvelity, Alzheimer's, argenx, Vyvgart, Enhertu, Leqembi, ASCO, Moderna, M&A, biotech IPO, Lilly, AstraZeneca, Gilead, Biogen